Cookies are used to help provide a better web service to patients and others.
Uses include: remembering products you add to our cart, understanding what people need and ensuring our website works properly.
Our service contains information about acquiring treatments that have been approved in another country. This includes professional information such as approval details, product information and pricing. By continuing, you are declaring that you are requesting any such information.
How to buy Kisqali (ribociclib): You can order Kisqali (ribociclib) from TheSocialMedwork if the medicine has not been approved or is not available in your country. We help patients and doctors get access to medicines at the lowest price worldwide.
Marketing Authorisation Holder
Novartis Europharm Limited
Mode of Action
Kinase inhibitor (targeted therapy)
Regulatory agency approval
European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Kisqali (ribociclib) is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer1,2.
How does Kisqali (ribociclib) work?
Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Before a cell can divide, it has to go through four phases: a growth phase (G1-phase), a synthesis phase (S-phase), another growth phase (G2-phase), and a last phase is where the cell divides (M-phase). Cancer cells divide exceedingly fast, passing through these 4 phases rapidly. Ribociclib blocks the progression from the first G1-phase, into the second S-phase. It does this by inhibiting the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) – two proteins that are involved in entering the S-phase1.
Where has Kisqali (ribociclib) been approved?
Kisqali (ribociclib) was approved in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive HER2-negative advanced or metastatic breast cancer by:
FDA (USA) on March 13, 20173
EMA (EU) on August 22, 20174
How is Kisqali (ribociclib) taken?
The standard dosage is:
600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days, followed by 7 days off treatment (one complete cycle consists of 28 days).
Dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability.
Complete information about Kisqali (ribociclib) dosage and administration can be found in the resources section.
Consult your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Kisqali (ribociclib)
Most common adverse reactions (incidence ≥ 20%) are1,4:
The efficacy of Kisqali (ribociclib) was assessed in a randomised, double-blind, placebo-controlled, multicenter clinical study (MONALEESA-2) which compared ribociclib plus letrozole (N=334) to placebo plus letrozole (N=334) in a total of 668 postmenopausal women with HR-positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease1,2.
The median progression-free survival (PFS) (at the 2/01/2017 cutoff) was 25.3 months ribociclib plus letrozole group (95% CI: 23.0, 30.3) and 16.0 months (95% CI 13.4, 18.2) in the placebo group. The overall response rate was 54.5% in the ribociclib plus letrozole group (95% CI: 48.4, 60.6) and 38.8% (95% CI 32.7, 44.9) in the placebo plus letrozole group2.
During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.
Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.
You can order and receive your medicine in 5 simple steps
Talk to your doctor
Place order and send prescription
Pay for order
Check documents for delivery
Receive your medicine
Totally awesome! Keep up the great work you’re doing!
Need a medicine that’s not approved in your country?
We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.